SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple stock experienced volatility during a product event where the company unveiled the iPhone Duo, its first foldable smartphone, alongside the iPhone 18 Pro series and updated wearables. While some traders expressed skepticism regarding the high price point and late entry into the foldable market, retail sentiment remained mixed as they debated the potential for a "sell the news" reaction versus long-term growth.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a record-breaking second-quarter operating income and an insider purchase of 55,000 shares by director Lawrence Cheng. The community is actively debating the company's future direction, particularly regarding its strategic stake in eBay and the lack of communication on an earnings call, with retail traders split between bullish sentiment on valuation and frustration over price stagnation.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is trending following the announcement of a massive share buyback and cancellation program, which investors view as a signal of management's confidence in long-term growth despite recent market volatility. The community remains focused on the company's dominant position in the High Bandwidth Memory (HBM) market and its role in AI infrastructure, though some traders express skepticism regarding the impact of recent Korean regulatory measures on the stock's performance.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending as traders speculate on a major bounce ahead of upcoming earnings, with many viewing the current price as a buying opportunity supported by strong contract backlogs. Debate remains divided between those expecting a sharp reversal fueled by institutional accumulation and others predicting further downside if the company fails to deliver positive guidance.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending as investors react to a significant double-digit selloff, with discussion centered on whether the decline represents an unhealthy pullback or a buying opportunity for the AI infrastructure provider. Traders are debating the lack of a clear fundamental catalyst while monitoring key technical support levels to gauge when the stock might recover from the recent volatility.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan shares fell significantly after the company issued third-quarter revenue guidance that arrived below Street expectations, overshadowing a solid earnings beat. While some traders view the double-digit drop as a major overreaction and a buying opportunity, others express concern over management changes and a potential for further near-term volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following mixed reactions to positive Phase 3 IZAR-1 trial results in psoriatic arthritis, which met primary endpoints but were perceived by some traders as failing to show a clear best-in-class advantage over competitors. Investors remain divided, with many expressing frustration over company management and recent financing moves while others maintain confidence in the firm's long-term potential, citing strong clinical safety profiles and upcoming catalysts.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics is trending after reporting positive Phase 3 clinical trial results for its phentolamine ophthalmic solution in treating presbyopia, which met its primary endpoint. While some traders view the data as a positive catalyst for an eventual FDA submission, others are expressing concern regarding potential dilution or questioning the long-term management strategy.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

The discussion is fragmented between traders expressing frustration over the lack of near-term price movement and long-term investors focusing on the company's fundamental growth, specifically the commercial expansion of Recorlev and upcoming Phase 3 trials for XP-8121. While some traders are exiting their positions, others view the recent price consolidation as a buying opportunity given the company's path to profitability and high institutional ownership.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing downward price pressure and investor frustration despite beating earnings expectations and raising guidance, with market sentiment favoring Eli Lilly's stronger growth momentum and pipeline perception. The stock's performance reflects skepticism regarding the competitive impact of alternative obesity treatments and the pace of oral Wegovy's revenue contribution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.read more...

HC Wainwright Issues Pessimistic Outlook for CBIO Earnings

Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) - Research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Crescent Biopharma in a note issued to investors on Monday, May 4th. HC Wainwright analyst M. Kapoor now forecasts that the biopharmaceutic...

Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3% - Here's Why

Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 8.3% - Here's Why...

Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell?

Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat...

Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Stock Price Passes Above 200 Day Moving Average - What's Next...

Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving Average - Time to Sell?

Crescent Biopharma (NASDAQ:CBIO) Share Price Passes Above 200 Day Moving Average - Should You Sell...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and three h...

Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded Crescent Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright

HC Wainwright decreased their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday...

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Crescent Biopharma Inc.

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today

Equity

Bearish Sentiment

Yes, day one

Yes, but I'll wait for reviews

No, too expensive

No, not interested in a foldable

Apple unveiled its first foldable iPhone, reportedly called the iPhone Duo, at its September 9 event, with pricing starting at $2,000 for the 256GB model. Will you buy the $2,000 iPhone Duo? Vote and explain your reasoning in the comments.

Apple ($AAPL) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Stocktwits

) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Feed

News

Sentiment

Fundamentals

Info

CBIO Crescent Biopharma Inc.

Fundamentals

Latest CBIO News